Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Linezolid versus vancomycin in Methicillin Resistant Staphylococcus aureus nosocomial pneumonia in the elderly.

Dupont J, Prat D, Sztrymf B.

Am J Emerg Med. 2017 Aug;35(8):1197-1198. doi: 10.1016/j.ajem.2017.05.043. Epub 2017 May 26. No abstract available.

PMID:
28576638
2.

Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.

Alaniz C, Pogue JM.

Ann Pharmacother. 2012 Oct;46(10):1432-5. doi: 10.1345/aph.1R221. Epub 2012 Sep 4.

PMID:
22947593
3.

Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.

Patel DA, Shorr AF, Chastre J, Niederman M, Simor A, Stephens JM, Charbonneau C, Gao X, Nathwani D.

Crit Care. 2014 Jul 22;18(4):R157. doi: 10.1186/cc13996.

4.

Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: controversy continues.

Masuta K, Oba Y, Iwata K.

Clin Infect Dis. 2012 Jul;55(1):161. doi: 10.1093/cid/cis331. Epub 2012 Mar 29. No abstract available.

PMID:
22460960
5.

Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.

Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J.

Clin Infect Dis. 2012 Mar 1;54(5):621-9. doi: 10.1093/cid/cir895. Epub 2012 Jan 12.

PMID:
22247123
6.

Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.

Puzniak LA, Morrow LE, Huang DB, Barreto JN.

Clin Ther. 2013 Oct;35(10):1557-70. doi: 10.1016/j.clinthera.2013.08.001. Epub 2013 Sep 3.

PMID:
24011955
7.

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses.

Powers JH, Ross DB, Lin D, Soreth J.

Chest. 2004 Jul;126(1):314-5; author reply 315-6. No abstract available.

PMID:
15249482
8.

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH.

Chest. 2003 Nov;124(5):1789-97.

PMID:
14605050
9.

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.

Chastre J, Blasi F, Masterton RG, Rello J, Torres A, Welte T.

Clin Microbiol Infect. 2014 Apr;20 Suppl 4:19-36. doi: 10.1111/1469-0691.12450. Review.

10.

Linezolid limits burden of methicillin-resistant Staphylococcus aureus in biofilm of tracheal tubes.

Fernández-Barat L, Ferrer M, Sierra JM, Soy D, Guerrero L, Vila J, Li Bassi G, Cortadellas N, Martínez-Olondris P, Rigol M, Esperatti M, Luque N, Saucedo LM, Agustí C, Torres A.

Crit Care Med. 2012 Aug;40(8):2385-9. doi: 10.1097/CCM.0b013e31825332fc.

PMID:
22622402
11.

Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.

De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S, Müller E, Piecyk A, Reisinger E, Resch A.

Infection. 2009 Apr;37(2):123-32. doi: 10.1007/s15010-008-8046-7. Epub 2009 Mar 9.

PMID:
19277465
12.
13.

Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.

Maclayton DO, Hall RG 2nd.

Ann Pharmacother. 2007 Feb;41(2):235-44. Epub 2007 Feb 13. Review.

PMID:
17299012
14.

Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: A retrospective cohort analysis: Effectiveness of linezolid in the elderly.

Takada H, Hifumi T, Nishimoto N, Kanemura T, Yoshioka H, Okada I, Kiriu N, Inoue J, Koido Y, Kato H.

Am J Emerg Med. 2017 Feb;35(2):245-248. doi: 10.1016/j.ajem.2016.10.058. Epub 2016 Oct 29.

PMID:
27832976
15.

Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.

Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, Dong W, Xing J, Dong Y.

Eur J Clin Pharmacol. 2015 Jan;71(1):107-15. doi: 10.1007/s00228-014-1775-x. Epub 2014 Oct 30. Review.

PMID:
25355172
16.

The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.

Chavanet P.

Med Mal Infect. 2013 Dec;43(11-12):451-5. doi: 10.1016/j.medmal.2013.09.011. Epub 2013 Nov 13.

PMID:
24238896
17.

Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Segarra-Newnham M, Church TJ.

Ann Pharmacother. 2012 Dec;46(12):1678-87. doi: 10.1345/aph.1R370. Epub 2012 Dec 11. Review.

PMID:
23232021
18.
19.

Vancomycin for methicillin-resistant Staphylococcus aureus pneumonia: the good, the bad, and the ugly.

Kollef MH.

Crit Care Med. 2012 Jan;40(1):330-2. doi: 10.1097/CCM.0b013e31822e5741. No abstract available.

PMID:
22179367
20.

Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.

Daniel Mullins C, Kuznik A, Shaya FT, Obeidat NA, Levine AR, Liu LZ, Wong W.

Clin Ther. 2006 Aug;28(8):1184-1198. doi: 10.1016/j.clinthera.2006.08.016.

PMID:
16982296

Supplemental Content

Support Center